# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Amarin Corp (NASDAQ:AMRN) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.04) b...
Under the terms of the PLA, Vascepa will be reimbursed as a Special Authority product by Alberta Health for the secondary preve...
Cantor Fitzgerald analyst Louise Chen reiterates Amarin Corp (NASDAQ:AMRN) with a Overweight.
Cantor Fitzgerald analyst Louise Chen reiterates Amarin Corp (NASDAQ:AMRN) with a Overweight.